Teva Launches Social Media Campaign on Optimal Inhaler Use
Teva Pharmaceuticals Europe announced the launch of its Get It Right disease awareness campaign. The campaign focuses on increasing awareness and dialogue on the correct usage of asthma inhalers. It aims to challenge the public’s and physician’s min-set in managing asthma by calling attention to poor inhaler techniques while using social media and creating other media content and resources to educate people for World Asthma Day on May 2.
Using social media, the initiative is to spread the message by using hashtags #Getitright and #worldasthmaday. Additionally, a livestream broadcast will be provided to healthcare professionals on June 6, entitled Breathing New Life Into Inhalation Technology – Inside Out, An Exploration of Inhalers. The webinar will be chaired by Prof. Dr. J. Christian Virchow, Head of Department of Pneumology, University of Rostock, Germany will speak to the do’s and don’ts of inhaler techniques and how to help those affected by asthma. To register for the broadcast visit http://letstalkrespiratory.eu/inhalationtechnology
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
